Abstract
In a study of 50 patients with uncomplicated arterial hypertension the administration of hydrochlorothiazide, 50 to 100 mg daily or every other day, with or without reserpine, 0.25 mg daily, resulted in a fall in the mean blood pressure from 182/113 to 144/92 mm Hg. The mean duration of therapy was 19 months. The mean serum potassium concentration was 4.3 mmol/l before the onset of therapy. It fell during the first 6 weeks of treatment, but seldom below 3.5 mmol/l, then rose gradually and spontaneously to 4.1 mmol/l after 19 months of therapy. All the patients remained asymptomatic. These findings bring into question the routine use of potassium supplements or a potassium-sparing diuretic, such as spironolactone or triamterene, during the treatment of hypertension with diuretics such as the thiazides. The use of potassium supplements or a potassium-sparing agent may induce hyperkalemia in spite of the simultaneous administration of a diuretic that acts more proximally. Since hyperkalemia is potentially lethal, the serum potassium concentration should be carefully monitored in any patient receiving potassium supplements or a potassium-sparing agent.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Cohen A. B. Hyperkalemic effects of triamterene. Ann Intern Med. 1966 Sep;65(3):521–527. doi: 10.7326/0003-4819-65-3-521. [DOI] [PubMed] [Google Scholar]
- Greenblatt D. J., Koch-Weser J. Adverse reactions to spironolactone. A report from the Boston Collaborative Drug Surveillance Program. JAMA. 1973 Jul 2;225(1):40–43. doi: 10.1001/jama.225.1.40. [DOI] [PubMed] [Google Scholar]
- Kassirer J. P., Harrington J. T. Diuretics and potassium metabolism: a reassessment of the need, effectiveness and safety of potassium therapy. Kidney Int. 1977 Jun;11(6):505–515. doi: 10.1038/ki.1977.67. [DOI] [PubMed] [Google Scholar]
- Kosman M. E. Management of potassium problems during long-term diuretic therapy. JAMA. 1974 Nov 4;230(5):743–748. [PubMed] [Google Scholar]
- Lemieux G., Beauchemin M., Gougoux A., Vinay P. Treatment of arterial hypertension with tienilic acid, a new diuretic with uricosuric properties. Can Med Assoc J. 1978 May 6;118(9):1074–1078. [PMC free article] [PubMed] [Google Scholar]
- McNay J. L., Oran E. Possible predisposition of diabetic patients to hyperkalemia following administration of potassium-retaining diuretic, amiloride (MK 870). Metabolism. 1970 Jan;19(1):58–70. doi: 10.1016/0026-0495(70)90118-6. [DOI] [PubMed] [Google Scholar]
- Myers M. G. New drugs in hypertension. Can Med Assoc J. 1977 Jan 22;116(2):173–176. [PMC free article] [PubMed] [Google Scholar]
- Page L. B., Sidd J. J. Medical management of primary hypertension . 3. N Engl J Med. 1972 Nov 23;287(21):1074–1081. doi: 10.1056/NEJM197211232872106. [DOI] [PubMed] [Google Scholar]
- Spino M., Sellers E. M., Kaplan H. L., Stapleton C., MacLeod S. M. Adverse biochemical and clinical consequences of furosemide administration. Can Med Assoc J. 1978 Jun 24;118(12):1513–1518. [PMC free article] [PubMed] [Google Scholar]
- Wilkinson P. R., Issler H., Hesp R., Raftery E. B. Total body and serum potassium during prolonged thiazide therapy for essential hypertension. Lancet. 1975 Apr 5;1(7910):759–762. doi: 10.1016/s0140-6736(75)92432-0. [DOI] [PubMed] [Google Scholar]